Michael W. Nall
Net Worth
Last updated:
What is Michael W. Nall net worth?
The estimated net worth of Mr. Michael W. Nall is at least $7,395,800 as of 19 Oct 2016. He has received compensation worth at least $7,395,800 in Biocept, Inc..
What is the salary of Michael W. Nall?
Mr. Michael W. Nall salary is $739,580 per year as Chief Executive Officer, Pres & Director in Biocept, Inc..
How old is Michael W. Nall?
Mr. Michael W. Nall is 62 years old, born in 1963.
What stocks does Michael W. Nall currently own?
As insider, Mr. Michael W. Nall owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Biocept, Inc. (BIOC) | Chief Executive Officer, Pres & Director | 36,363 | $0 | $0 |
What does Biocept, Inc. do?
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Michael W. Nall insider trading
Biocept, Inc.
Biocept key executives
Biocept, Inc. executives and other stock owners filed with the SEC:
- Mr. Michael Terry (70) Senior Vice President of Corporation Devel.
- Mr. Michael W. Nall (62) Chief Executive Officer, Pres & Director
- Mr. Timothy C. Kennedy (67) Chief Financial Officer, Chief Operating Officer & Corporation Sec.